Switchable PDT for reducing skin photosensitization by a NIR dye inducing self-assembled and photo-disassembled nanoparticles.
Photodynamic therapy (PDT) is the combination of light and photosensitizer (PS) to kill tumor cells, which has the potential to meet many currently unmet medical needs. However, the whole body distribution and activatability by sunlight of photosensitizers to induce skin photosensitivity have limited the extensive clinic application of PDT. Herein, a novel strategy is presented to overcome these limitations by using a hydrophobic Near-infared (NIR) dye IR-780 iodide (IR780) to induce the self-assembly of albumin-PS conjugates, as a switchable PDT (Switch-PDT) agent. The PDT effect of PS is effectively inhibited by IR780 and recovered by NIR light irradiation in vitro. This quench/recovery strategy dose not sacrifice the anti-tumor ability in vivo, and the combined PDT and PTT (photothermal) effect contributes a very effective tumor inhibition rate of 100%. More importantly, the PDT effect is significantly suppressed after intravenous administration in mice or subcutaneous administration in rabbits as exhibited by the negligible skin response, while traditional PDT agent arouses severe skin erythema and edema. To the best of our knowledge, the switchable PDT is the first time to be used to eradicate the skin photosensitization of PS in vivo.
State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China.
Yifan
Y
Zhang
State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China.
Lingyi
L
He
State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China.
Jie
J
Wu
State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China.
Kaikai
K
Wang
State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China.
Juan
J
Wang
State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China.
Weimin
W
Dai
State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China; Institute of Drug R&D, Medical School of Nanjing University, Nanjing 210093, China; Jiangsu R&D Platform for Controlled & Targeted Drug Delivery, Nanjing University, Nanjing 210093, China; Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing 210093, China.
Ahu
A
Yuan
State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China; Institute of Drug R&D, Medical School of Nanjing University, Nanjing 210093, China; Jiangsu R&D Platform for Controlled & Targeted Drug Delivery, Nanjing University, Nanjing 210093, China; Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing 210093, China. Electronic address: wuj@nju.edu.cn.
Jinhui
J
Wu
State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing 210093, China; Institute of Drug R&D, Medical School of Nanjing University, Nanjing 210093, China; Jiangsu R&D Platform for Controlled & Targeted Drug Delivery, Nanjing University, Nanjing 210093, China; Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing 210093, China.
Yiqiao
Y
Hu
D000818:Animals; D004396:Coloring Agents / Q000008:administration & dosage / Q000737:chemistry; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D007259:Infrared Rays / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods*; D010787:Photosensitivity Disorders / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011855:Radiodermatitis / Q000209:etiology* / Q000517:prevention & control; D012867:Skin / Q000187:drug effects / Q000528:radiation effects*; D016896:Treatment Outcome
C548458:2-(2-(2-chloro-3-((1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene)-1-cyclohexen-1-yl)ethenyl)-3,3-dimethyl-1-propylindolium; D004396:Coloring Agents; D007211:Indoles; D053769:Nanocapsules; D017319:Photosensitizing Agents
NIR dye bridge; Photo-disassembly; Skin photosensitization; Switchable PDT; Tumor ablation